SOST and osteoporosis: Besides the emerging anti-sclerostin antibodies, which promote bone formation by increasing canonical WNT–β-catenin signaling in osteoblasts, therapeutic options for osteoporosis or cancer-induced bone disease are lacking50, highlighting the unmet medical need for osteoanabolic agents.